Bullfrog AI (BFRG) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
5 Oct, 2026Executive summary
Virtual annual meeting scheduled for September 18, 2025; July 29, 2025 record date with 10,081,340 common shares outstanding.
Board recommends voting FOR all proposals: election of four directors and ratification of M & K CPAs, PLLC for FY2025.
Proxy materials made available primarily online beginning August 8, 2025, with paper copies available on request.
Voting matters and shareholder proposals
Proposal 1 elects four incumbent nominees for terms through the next annual meeting; directors are elected by plurality, and withheld votes and broker non-votes have no effect.
Proposal 2 seeks ratification of M & K CPAs, PLLC for the fiscal year ending December 31, 2025; approval requires a majority of votes cast.
Stockholder proposals for inclusion in the 2026 proxy materials are due April 30, 2026; other proposals require notice by May 31, 2026.
Board of directors and corporate governance
Four nominees: Vininder Singh, R. Donald Elsey, William Enright and Jason D. Hanson; Elsey, Enright and Hanson were determined independent under Nasdaq standards.
Singh serves as both CEO and Board Chair; the Board considers the combined roles beneficial to operations and strategic oversight.
In FY2024, the Board met five times; Audit Committee met five times, Compensation Committee four times and Nominating & Corporate Governance Committee four times; directors attended all meetings they served on.
Each standing committee has three members; committee chairs are Elsey for Audit, Enright for Compensation and Hanson for Nominating & Corporate Governance.
Latest events from Bullfrog AI
- AI platform targets drug discovery economics, backed by a pharma deal and expanding pipeline.BFRG
LD Micro 20th Annual Main Event Conference - A warrant-resale registration amid early-stage drug development and ongoing funding needs.BFRG
Registration filing - Resale registration could yield up to $3.26M, contingent on cash warrant exercises.BFRG
Registration filing - Four proposals seek a $10M equity facility, reverse-split authority and expanded equity awards.BFRG
Proxy filing - A $100 million shelf backs an early-stage AI drug strategy facing financing and clinical risks.BFRG
Registration filing - Four director nominees and M & K auditor ratification anchor the 2024 virtual meeting agenda.BFRG
Proxy filing - Votes cover financing dilution, a discretionary reverse split and a 750,000-share Plan increase.BFRG
Proxy filing - Amendment updates Item 16 and auditor consent; the continuous-offering framework remains.BFRG
Registration filing - A conditional $10 million equity facility brings potential liquidity and substantial dilution risk.BFRG
Registration filing